Review Article
Gilbert Glady
Abstract
Background: Oral immunotherapy has become a recognized method, validated by numerous publications and its use has developed in the current practice of an allergy clinic. We propose an immunotherapy administered by the sublingual route which is both more flexible than the immunotherapies already known for systemic use, devoid of any risk of side effects and equally effective in terms of therapeutic efficacy. The aim of such a therapy will clearly be that of a slow regulation of the molecular imbalances in relation to the state of allergy and a progressive recovery of the cellular homeostasis. Methods and findings: For this purpose, we first resort to a regulation taking place at the epigenetic level thanks to the introduction in our therapeutic methodology of microRNAs used for their remarkable posttranscriptional regulatory action. All components of our cures are prepared in ultra-low doses to avoid any noxious side effects and administered per sublingual way. But the BioImmune(G)ene Medicine - BI(G)MED in shortcut - is also holistic in the sense that it does not just act in a regulating way on the immunogenetic mechanisms involved directly in the genesis of allergic diseases, but also search for neutralizing infectious, viral and bacterial and even fungal agents, which have a pernicious influence on the course of clinical allergic phenomena. To achieve this result, the BI(G)MED uses a wide range of biological tests to measure the patient's reaction potential at the immunogenetic level and the impact of infectious agents in direct interaction with the immune system. Conclusion: The description of clinical cases with their therapeutic modalities will make it possible to highlight the regulatory properties of this new method referring to the self-regulation potential inherent in cellular homeostasis. Keywords: Allergic asthma; Innovative sublingual immunotherapy; microRNAs; Systems biology; Th1/Th2 balance